“This test requires just one millimeter of cancer on a biopsy on five consecutive slides,” says Eric A. Klein, MD.
JCO Precision Oncology recently published the paper, “GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer–Specific Mortality.” In this video, senior author Eric A. Klein, MD, discusses the background behind the study and what impresses him about the Oncotype DX Genomic Prostate Score. Klein is the Chairman of the Glickman Urological & Kidney Institute and a staff member in the Taussig Cancer Institute at Cleveland Clinic.
Polygenic score-adjusted PSA may improve screening accuracy in prostate cancer
June 2nd 2023“We showed that genetic correction of PSA levels has the potential to both reduce unnecessary biopsies and improve our ability to detect tumors with a more aggressive profile," says Linda Kachuri, PhD, MPH.
2 Clarke Drive
Cranbury, NJ 08512